|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Research |
1 Department of Ultrasound, School of Oncology, Peking University, 52 Fu-cheng
Rd., Beijing 100036, People's Republic of China.
2 Department of Pathology, School of Oncology, Peking University, Beijing
100036, People's Republic of China.
OBJECTIVE. The objective of our study was to evaluate the clinical utility of performing contrast-enhanced sonography before percutaneous biopsy of focal liver lesions.
SUBJECTS AND METHODS. One hundred eighty-six patients with focal
liver lesions detected on either sonography or contrast-enhanced CT were
randomly divided into two groups: a group who underwent contrast-enhanced
sonography and another who underwent unenhanced sonography. The
contrast-enhanced sonography group (79 patients, 129 lesions) underwent
SonoVue-enhanced sonography before biopsy, and the unenhanced sonography group
(107 patients, 143 lesions) did not undergo contrast-enhanced sonography
before biopsy. Conventional sonography was used in all patients to guide the
biopsy procedures. The pathologic diagnosis was considered definitive and
final if the biopsy result was malignant. If the initial biopsy result was
benign or negative for malignancy, then the result was either confirmed or
denied on the basis of contrast-enhanced CT, MRI, angiography, serum
-fetoprotein level, or clinical follow-up over a period of 6 months. In
some patients with suspected malignancy, biopsy was repeated when considered
necessary during the follow-up. The diagnostic accuracy of the initial biopsy
was defined as the percentage of the total number of lesions that were
correctly diagnosed at the initial biopsy. The difference in diagnostic
accuracy between the two groups was analyzed to evaluate the value of
performing contrast-enhanced sonography before biopsy.
RESULTS. Of the 129 lesions in the contrast-enhanced sonography
group, 28 (21.7%) were benign and 101 (78.3%) were malignant. Of the 143
lesions in the unenhanced sonography group, 36 (25.2%) were benign and 107
(74.8%) were malignant. There was no significant difference in the
distribution of malignant and benign lesions in these two groups (p
> 0.05). There was no statistically significant difference in the
distribution of lesions by size between the contrast-enhanced and unenhanced
sonography groups (
2 = 0.619, p > 0.05). The
diagnostic accuracy of the initial biopsy was significantly higher in the
contrast-enhanced sonography group than in the unenhanced sonography group
(95.3% vs 87.4%, respectively; p < 0.05). The diagnostic accuracy
of the initial biopsy for malignant lesions
2.0 cm was also significantly
higher in the contrast-enhanced sonography group than in the unenhanced
sonography group (97.1% vs 78.8%, respectively; p < 0.05). No
major complications occurred in our study except one case of pneumothorax in
the unenhanced sonography group.
CONCLUSION. Contrast-enhanced sonography before percutaneous focal
liver lesion biopsy improved the diagnostic accuracy of the procedure by
providing important intralesional information for differentiating viable,
denaturalized, or necrotic tissue; consequently, by providing more accurate
information about the site of biopsy even in lesions
2.0 cm,
contrast-enhanced sonography before biopsy reduced the number of puncture
attempts.
Keywords: biopsy contrast-enhanced sonography hepatocellular carcinoma liver disease liver neoplasms
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |